CompanyGraphAt a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionReturn on equity is 68.9%, higher than 95% of its Biotechnology peers (median -22.4%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.87BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
52-Week Change
208.79%vs all stocks
Market Capitalization
4.87BUSDvs all stocks (USD)
Enterprise Value
4.05BUSDvs all stocks (USD)
Forward P/E
-43.38xvs Biotechnology peers
Price to Book (MRQ)
5.99xvs Biotechnology peers
Enterprise to EBITDA
-57.87xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-54.63%vs Biotechnology peers
Return on Equity (TTM)
68.90%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Sep 28, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
0.00USDvs all stocks (USD)
Net Income (TTM)
-104.29MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-78.30MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-83.37MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-71.56MUSDvs all stocks (USD)
Pre-tax Income
-70.00MUSDFY2025 · Dec 31, 2025Income Tax Expense
0.00USDFY2025 · Dec 31, 2025Net Income
-70.00MUSDFY2025 · Dec 31, 2025EBIT
-70.00MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-70.00MUSDFY2025 · Dec 31, 2025Research & Development
62.06MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
10.28MUSDFY2025 · Dec 31, 2025Other Operating Expenses
-790.00KUSDFY2025 · Dec 31, 2025Non-operating Interest Income
1.56MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
0.00USDFY2025 · Dec 31, 2025EPS (Basic)
-2.38USDFY2025 · Dec 31, 2025EPS (Diluted)
-2.38USDFY2025 · Dec 31, 2025Basic Shares Outstanding
35.08MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
35.08MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-70.00MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-67.88MUSDFY2025 · Dec 31, 2025Free Cash Flow
-67.90MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
21.77MUSDFY2025 · Dec 31, 2025Income Tax Paid
0.00USDFY2025 · Dec 31, 2025Interest Paid
0.00USDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-70.00MUSDFY2025 · Dec 31, 2025Stock-based Compensation
1.44MUSDFY2025 · Dec 31, 2025Other Non-cash Items
839.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-122.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-39.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-24.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-143.85MUSDFY2025 · Dec 31, 2025Sale of Investments
25.02MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-118.86MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
0.00USDFY2025 · Dec 31, 2025Other Financing Charges
-447.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
158.99MUSDFY2025 · Dec 31, 2025Shares Outstanding
41.78MSharesUpdated Sep 28, 2026Float Shares
32.29MSharesUpdated Sep 28, 2026Shares Short
4.11MSharesUpdated Sep 28, 2026Short Ratio
7.08daysvs all stocks
Short % of Shares Outstanding
15.09%vs all stocks
% Held by Insiders
2.49%vs all stocks
% Held by Institutions
98.33%vs all stocks
Total Cash (MRQ)
819.89MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
19.62USDUpdated Sep 28, 2026Total Debt (MRQ)
428.00KUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0005xvs Biotechnology peers
Current Ratio (MRQ)
70.53xvs Biotechnology peers
Book Value per Share (MRQ)
19.47USDUpdated Sep 28, 2026Total Assets
152.62MUSDvs all stocks (USD)
Total Current Assets
152.49MUSDFY2025 · Dec 31, 2025Total Liabilities
273.63MUSDFY2025 · Dec 31, 2025Total Non-current Assets
125.00KUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
264.48MUSDFY2025 · Dec 31, 2025Total Current Liabilities
9.15MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
21.77MUSDFY2025 · Dec 31, 2025Other Short-term Investments
120.10MUSDFY2025 · Dec 31, 2025Accounts Payable
2.13MUSDFY2025 · Dec 31, 2025Other Current Liabilities
47.00KUSDFY2025 · Dec 31, 2025Long-term Debt
4.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
1.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-123.42MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
-121.01MUSDvs all stocks (USD)
52-Week Low
32.00USDUpdated Sep 28, 202652-Week High
131.24USDUpdated Sep 28, 202652-Week Change
208.79%vs all stocks
50-Day MA
106.69USDUpdated Sep 28, 2026200-Day MA
89.01USDUpdated Sep 28, 2026Avg 10-Day Volume
972.40KSharesUpdated Sep 28, 2026Avg 30-Day Volume
695.76KSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-2.49USDUpdated Sep 28, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is 68.9%, higher than 95% of its Biotechnology peers (median -22.4%)Significant
Return on equity: 0.69Industry median: -0.22Industry P95: 0.23Peers compared: 184
Current ratio is 70.53×, higher than 95% of its Biotechnology peers (median 5.15×)Significant
Current ratio: 70.53Industry median: 5.15Industry P95: 22.16Peers compared: 184
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.12×)Notable
Debt-to-equity: 0.00Industry median: 0.12Industry P5: 0.00Peers compared: 184
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.59
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 35,820,060.775
Market cap is $4.87B, above the global median of $1.2BNotable
Market cap (USD): 4,870,310,453Global Median: 1,201,862,193
Companies that share the same coordination system — how they create, deliver, or capture value.
Definium Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai RAAS Blood Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Beijing Tong Ren Tang Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Haemonetics Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Dianthus Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Henlius Biotech, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Iovance Biotherapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Erasca, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Salubris Pharmaceuticals Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule